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Objectives. To systematically review and meta-analyze the eﬀectiveness of yoga for menopausal symptoms. Methods. Medline,
Scopus, the Cochrane Library, and PsycINFO were screened through April 2012. Randomized controlled trials (RCTs) were
included if they assessed the eﬀect of yoga on major menopausal symptoms, namely, (1) psychological symptoms, (2) somatic
symptoms, (3) vasomotor symptoms, and/or (4) urogenital symptoms. For each outcome, standardized mean diﬀerences (SMDs)
and 95% confidence intervals (CIs) were calculated. Two authors independently assessed risk of bias using the risk of bias tool
recommended by the Cochrane Back Review Group. Results. Five RCTs with 582 participants were included in the qualitative
review, and 4 RCTs with 545 participants were included in the meta-analysis. There was moderate evidence for short-term
eﬀects on psychological symptoms (SMD = −0.37; 95% CI −0.67 to −0.07; P = 0.02). No evidence was found for total
menopausal symptoms, somatic symptoms, vasomotor symptoms, or urogenital symptoms. Yoga was not associated with serious
adverse events. Conclusion. This systematic review found moderate evidence for short-term eﬀectiveness of yoga for psychological
symptoms in menopausal women. While more rigorous research is needed to underpin these results, yoga can be preliminarily
recommended as an additional intervention for women who suﬀer from psychological complaints associated with menopause.
1. Introduction
Menopause is defined as the permanent cessation of ovarian
function and is thereby the end of a woman’s reproductive
phase [1]. Menopause begins around the age of 50 years [2]
and is characterized by at least 12 months of amenorrhea
[3]. While it is an inevitable part of every woman’s life,
about 3 out of every 4 women experience complaints
during menopause [4, 5]. The most common menopausal
symptoms include hot flashes, night sweats, fatigue, pain,
decreased libido, and mood changes [6–8]. These symp-
toms often persist for several years postmenopause [9].
While hormone replacement therapy can eﬀectively reduce
menopausal symptoms [10, 11], its safety has long been
controversially discussed [10–12]. While the most recent
research has shown relatively low risk of severe adverse
events for hormone replacement within the first 10 years of
menopausal onset [10, 11, 13], the long-standing uncertainty
about its safety has nevertheless led to significant decreases
in hormone prescriptions to menopausal women [14].
Nonhormonal pharmacologic therapies have been shown to
be less eﬀective than hormonal therapy and to be associated
with their own adverse events that restrict their use for many
women [15]. Therefore, many menopausal women use com-
plementary therapies to cope with their symptoms [16–21],
and yoga is among the most commonly used complementary
therapies for menopausal symptoms [18–21].
An estimated 15 million American adults report having
practiced yoga at least once in their lifetime, almost half
of those using yoga explicitly for coping with symptoms
or promoting health [22]. Deriving from ancient Indian
philosophy, yoga comprises physical postures as well as
advice for ethical lifestyle and spiritual practice with the
ultimate goal of uniting mind, body, and spirit [23, 24].
In North America and Europe, yoga is most often associ-
ated with physical postures (asana), breathing techniques
(pranayama), and meditation (dyana) [24]. A variety of yoga
schools have evolved from the traditional Indian system of
yoga inWestern societies, which are giving diﬀerent weight to
physical and spiritual practice [24]. Yoga interventions have
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been shown to decrease anxiety [25], distress [26], blood
pressure [26], pain [27, 28], and fatigue [29].
A systematic review that included studies until mid of
2008 concluded that the evidence was insuﬃcient to rec-
ommend yoga as an intervention for menopausal symptoms
[30]. In the meantime, further large studies on yoga for
menopausal symptoms have been published. Therefore, the
aim of this paper was to systematically assess and meta-
analyze the eﬀectiveness of yoga in women with menopausal
symptoms.
2. Methods
The review was planned and conducted in accordance
with PRISMA guidelines for systematic reviews and meta-
analyses [31] and the recommendations of the Cochrane
Collaboration [32, 33].
2.1. Literature Search. The literature search comprised the
following electronic databases from their inception through
April 2012: Medline (via Pubmed), Scopus, the Cochrane
Library, and PsycINFO. The literature search was constructed
around search terms for “yoga” and search terms for
“menopause” and adapted for each database as necessary.
The complete search strategy for Pubmed was as follows:
(“Yoga”[Mesh] OR yog∗[Title/Abstract]) AND (“Climacteric”
[Mesh] OR “Menopause”[Mesh] OR “Postmenopause”
[Mesh] OR “Perimenopause”[Mesh] OR “Hot Flashes”
[Mesh] OR menopaus∗[Title/Abstract] OR peri-menopaus∗
[Title/Abstract] OR perimenopaus∗[Title/Abstract] OR post-
menopaus∗[Title/Abstract] OR post-menopaus∗[Title/
Abstract] OR climact∗[Title/Abstract] OR hot-flash∗[Title/
Abstract] OR hot flash∗[Title/Abstract] OR hot-flush∗[Title/
Abstract] OR hot flush∗[Title/Abstract] OR night sweat∗
[Title/Abstract]). Additionally, reference lists of identified
original and review papers and the table of contents of the
International Journal of Yoga Therapy and Yoga Therapy
Today were searched manually.
Abstracts identified during literature search were
screened, and the full articles of potentially eligible studies
were read in full by 2 authors to determine whether they met
the inclusion criteria.
2.2. Inclusion Criteria. To be eligible, studies had to meet the
following conditions.
(1) Types of studies. Randomized controlled trials (RCTs)
were eligible. Studies were eligible only if they were
published as full paper in English, German, French,
or Norwegian language.
(2) Types of participants. Studies of adult women who
were experiencing menopausal or postmenopausal
symptoms were eligible.
(3) Types of interventions. Studies that compared yoga
interventions with no treatment or any active treat-
ment were eligible. Studies were excluded if yoga was
not the main intervention but a part of a multimodal
intervention, such as mindfulness-based stress reduc-
tion. Since in North America and Europe, physical
exercise is perceived as a main component of yoga
[24], studies examining meditation or yogic lifestyle
without physical component were also excluded. No
further restrictions were made regarding yoga tradi-
tion, length, frequency or duration of the program.
Cointerventions were allowed.
(4) Types of outcome measures. Studies were eligible if
they assessed major menopausal symptoms, namely,
(1) psychological symptoms (e.g., depression, anx-
iety, sleep disorders), (2) somatic symptoms (e.g.,
pain, fatigue), (3) vasomotor symptoms (e.g., hot
flashes, night sweats), and/or (4) urogenital symp-
toms (e.g., sexual dysfunctions, bladder problems).
2.3. Data Extraction. Two reviewers independently extracted
data on characteristics of participants (e.g., sample size,
inclusion criteria, age), characteristics of the intervention
and control (e.g., yoga tradition, program length, frequency
and duration), and outcome measures and results. If neces-
sary, discrepancies were rechecked with a third reviewer and
consensus achieved by discussion.
2.3.1. Risk of Bias in Individual Studies. Risk of bias was
assessed by 2 reviewers independently using the 12 criteria
(rating: yes, no, unclear) recommended by the Cochrane
Back Review Group [33]. These criteria assess risk of bias
on the following domains: selection bias, performance bias,
attrition bias, reporting bias, and detection bias. If necessary,
discrepancies were rechecked with a third reviewer and
consensus achieved by discussion. Studies that met at least 6
of the 12 criteria and had no serious flaw were rated as having
low risk of bias. Studies that met fewer than 6 criteria or had
a serious flaw were rated as having high risk of bias.
2.4. Data Analysis. Studies were analyzed separately for
short- and long-term followups. For the purpose of this
review, short-term followup was defined as the outcome
measures taken closest to 12 weeks after randomization and
long-term followup as measures taken closest to 12 months
after randomization [33].
2.5. Assessment of Overall Eﬀect Size. Meta-analyses were cal-
culated using Review Manager 5 software (Version 5.1, The
Nordic Cochrane Centre, Copenhagen) if at least 2 studies on
a specific outcome were available. If studies had two or more
control groups, the control groups for assessment of overall
eﬀect were selected in the following order of preference:
no treatment, attention control, and active comparator. A
random eﬀects model was used because it involves the
assumption of statistical heterogeneity between studies [32].
Standardized mean diﬀerences (SMD) with 95% confidence
intervals (CI) were calculated as the diﬀerence in means
between groups divided by the pooled standard deviation.
Where no standard deviations were available, they were
calculated from standard errors, confidence intervals or t
values [32]; or attempts were made to obtain the missing
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data from the trial authors by email. The magnitude of the
eﬀect size was calculated using Cohen’s categories with (1)
SMD = 0.2–0.5: small; (2) SMD = 0.5–0.8: moderate; (3)
SMD > 0.8: large eﬀect sizes [34].
Levels of evidence were determined according to previ-
ously published recommendations with (1) strong evidence:
consistent findings among multiple RCTs with low risk
of bias; (2) moderate evidence: consistent findings among
multiple high-risk RCTs and/or one low-risk RCT; (3)
limited evidence: one RCT with high risk of bias; (4)
conflicting evidence: inconsistent findings among multiple
RCTs; (5) No evidence: no RCTs [35].
2.6. Assessment of Heterogeneity. Statistical heterogeneity
between studies was quantified using the I2 statistics, a
measure of how much variance between studies can be
attributed to diﬀerences between studies rather than chance.
The following categories were used to calculate the magni-
tude of heterogeneity: I2 = 0–30%: no heterogeneity; I2 =
30–49%: moderate heterogeneity, I2 = 50–74%: substantial
heterogeneity; I2 = 75–100%: considerable heterogeneity
[32]. The Chi2 test was used to assess whether diﬀerences in
results are compatible with chance alone. A P value ≤ 0.10
was regarded to indicate significant heterogeneity [32].
2.7. Subgroup and Sensitivity Analyses. Subgroup analyses
were planned for type of control intervention (no treatment;
attention control; active comparator). To test the robustness
of significant results, sensitivity analyses were conducted for
studies with high versus low risk of bias.
If statistical heterogeneity was present in the respective
meta-analysis, subgroup and sensitivity analyses were also
used to explore possible reasons for heterogeneity.
2.8. Risk of Bias across Studies. If at least 10 studies were
included in a meta-analysis, funnel plots were generated
using Review Manager 5 software. Publication bias was
assessed by visual analysis with roughly symmetrical funnel
plots regarded to indicate low risk and asymmetrical funnel
plots regarded to indicate high risk of publication bias [36].
3. Results
3.1. Literature Search. The literature search revealed a total of
207 records. One additional record each was found in refer-
ence lists of identified review papers and the table of contents
of the International Journal of Yoga Therapy, respectively.
Seventy-one duplicates were excluded. Further 128 records
were excluded since they did not meet all inclusion criteria.
Ten full-text articles were assessed [37–46] and 5 articles
were excluded; 1 article did not assess menopausal symptoms
[37], 1 RCT was published in Korean language [38], and 3
articles reported additional outcome measures for already
included studies on the same participant population [39–
41]. Therefore, 5 RCTs with a total of 582 participants [42–
46] were included in qualitative analysis. One RCT did not
report standard deviations, nor standard errors, confidence
intervals or t-values [43]. Since the missing data could not be
obtained from the authors of the respective study by email,
this study was excluded from quantitative analysis. Finally,
4 RCTs with overall 545 participants were included in the
meta-analysis (Figure 1).
3.2. Study Characteristics. Characteristics of the sample,
interventions, outcome assessment, and results are shown
in Table 1. In the following, study characteristics will be
presented for all trials included in qualitative synthesis.
3.2.1. Setting and Participant Characteristics. Two RCTs orig-
inated from the USA [43, 45], 1 from Brazil [42] and 2 from
India [44, 46]. Studies were conducted at university medical
centers [37, 38, 40] or yoga institutes [44, 46]. Patients were
recruited from university medical center oncology units [43]
and gynecological outpatient clinics [42, 44] or by using
advertisements [42, 44–46].
Between 31.9% and 47.2% of women in each RCT were
postmenopausal (median: 46.4%). One study included only
women who experienced menopausal symptoms after breast
cancer treatment [43]. Participants’ mean age ranged from
45.6 years to 54.9 years with a median of 49.0 years. Between
0% and 82.6% of included participants were Caucasians with
a median of 81.1%.
3.2.2. Intervention Characteristics. Yoga traditions were het-
erogeneous between studies: 1 RCT each used Iyengar yoga
[45]; an integrated approach to yoga therapy [44]; yoga
of awareness [43]; a combination of Yogasana and Tibetan
yoga [42]; traditional Indian yoga [46], respectively. All yoga
programs included yoga postures and meditation/relaxation;
4 programs also encompassed breathing techniques [42–
44, 46]. Program length and intensity varied, ranging from
weekly sessions over 8 weeks [43] to daily sessions over 90
days [46]. Generally, frequency of interventions was much
higher in the Indian studies [44, 46] compared to the studies
conducted in North or South America [42, 43, 45]. Yoga was
taught by at least 1 certified and experienced yoga teacher in
2 trials [43, 45], while 3 studies did not state qualification of
yoga teachers [42, 44, 46].
Two RCTs compared yoga to no treatment [43, 46]; 1
RCT compared yoga to exercise [44]; 2 3-arm RCTs com-
pared yoga to no treatment and exercise [42, 45]. Program
length, frequency, and duration of the exercise control arms
were exactly matched with the yoga interventions in 2 studies
[42, 44], while the yoga and exercise intervention in the third
RCT were matched for total contact time [45].
3.2.3. Outcome Measures. Total menopausal symptoms were
assessed in 3 studies using the KuppermanMenopausal Index
[42], the Greene Climacteric Scale [45], or the Menopause
Rating Scale [46]. Psychological symptoms were assessed
in all 5 RCTs using either menopause-specific scales [43,
44, 46], generic questionnaires [42], or both [45]. Using
menopause-specific scales, somatic symptoms were assessed
by 4 RCTs [43–46]; vasomotor symptoms by 3 RCTs [43–
45]; urogenital symptoms by 2 RCTs [45, 46]. Only 1 RCT
reported safety data [42].
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207 of records identified through
database searching
5 of full-text articles excluded
1 of full-text articles excluded
2 of additional records identified
through other sources
10 of full-text articles
assessed for eligibility
5 of studies included in
qualitative synthesis
128 of records excluded
4 of studies included in
quantitative synthesis
(meta-analysis)
- 074 Medline
- 019 Cochrane
- 107 Scopus
- 007 PsycInfo
- 1 no menopausal symptoms
- 1 Korean language
- 3 multiple publications on the
same sample
- 1 insuﬃcient raw data
138 of records after
duplicates removed
Figure 1: Flowchart of the results of the literature search.
3.2.4. Risk of Bias in Individual Studies. Two RCTs had low
risk of bias [43, 46] and 3 RCTs had high risk of bias [42, 44,
45] (Table 2). Risk of selection bias mainly was low; all but
1 RCT [42] reported adequate randomization, while only 2
RCTs reported adequate allocation concealment [43, 46]. No
study reported blinding of participants or providers, while
2 studies reported adequate blinding of outcome assessors
[43, 45]. Only 1 study included an adequate intention-to-
treat analysis [43]. Risk of selective outcome reporting was
high in 2 studies that reported diﬀerent outcomes from the
same RCT in multiple publications without disclosing the
entire study protocol [44, 45].
3.3. Analyses of Overall Eﬀects. Meta-analyses did not reveal
evidence for short-term eﬀects on total menopausal symp-
toms (SMD = −0.53; 95% CI −1.19 to 0.14; P = 0.12;
heterogeneity: I2 = 85%; Chi2 = 13.05; P < 0.01). Moderate
evidence was found for short-term eﬀects on psychological
symptoms (SMD = −0.37; 95%CI−0.67 to−0.07; P = 0.02;
heterogeneity: I2 = 52%; Chi2 = 6.25; P = 0.10). Based on
Cohen’s categories, the eﬀects on psychological symptoms
were of small size. There was no evidence for short-term
eﬀects on somatic symptoms (SMD = −0.26; 95% CI −0.76
to 0.25; P = 0.32; heterogeneity: I2 = 83%; Chi2 = 11.99;
P < 0.01), vasomotor symptoms (SMD = −0.04; 95% CI
−0.68 to 0.60; P = 0.90; heterogeneity: I2 = 81%; Chi2 =
5.35; P = 0.02), or urogenital symptoms (SMD = −0.37;
95% CI −1.14 to 0.40; P = 0.34; heterogeneity: I2 = 89%;
Chi2 = 9.37; P < 0.01) (Figure 2).
Only 1 RCT included a longer-term followup for yoga
compared to no treatment. At 20-week followup, this study
reported significant group diﬀerences for psychological,
somatic, and vasomotor symptoms [43] (Table 1).
Only 1 RCT included safety data and reported that yoga
was not associated with any adverse events [42].
3.3.1. Subgroup and Sensitivity Analyses. When comparing
yoga to no treatment, there was no evidence for short-
term eﬀects on total menopausal symptoms, psychological
symptoms, somatic symptoms, or urogenital symptoms
(Table 3). When comparing yoga to exercise, there was
no evidence for short-term eﬀects on total menopausal
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−2 0 1 2−1
Favours yoga Favours control
Afonso et al., 2012 [42] 12.4 8.1 15 19.9 8.1 15 26.7% −0.90 [−1.66, −0.14]
Elavsky and McAuley,
2007 [45] 12.25 8.49 61 11.71 6.56 39 35.6% 0.07[−0.33, 0.47]
Joshi et al., 2011 [46] 4.36 4.8 90 9.2 6.72 90 37.7% −0.83 [−1.13, −0.52]
Total 166 144 100.0% −0.53 [−1.19, 0.14]
Heterogeneity: Chi2= 13.05, df =2 (P = 0.001); I2 = 85%
Test for overall eﬀect: Z = 1.56 (P = 0.12)
−2 0 1 2−1
Favours yoga Favours control
Afonso et al., 2012 [42] 11 7.4 15 14.8 7.4 15 12.7% −0.50 [−1.23, 0.23]
Chattha et al., 2008 [44] 3.65 2.76 54 4.74 3.04 54 27.7% −0.37 [−0.75, 0.01]
Elavsky and McAuley,
2007 [45]
6.88 5.58 61 6.79 4.58 39 26.3% 0.02 [−0.38, 0.42]
Joshi et al., 2011 [46] 1.85 2.73 90 3.37 3.31 90 33.3% −0.62 [−0.92, −0.32]
Total (95% CI) 220 198 100.0% −0.37 [−0.67,−0.07]
Heterogeneity: Chi2= 6.25, df =3 (P = 0.10); I2 = 52%
Test for overall eﬀect: Z = 2.40 (P = 0.02)
−2 0 1 2−1
Favours yoga Favours control
Chattha et al., 2008 [44] 2.16 1.74 54 2.16 2.04 54 32.8% 0.00 [−0.38, 0.38]
Elavsky and McAuley,
2007 [45]
2.75 2.4 61 2.76 2.42 39 32.0% −0.00 [−0.41, 0.40]
Joshi et al., 2011 [46] 1.61 1.91 90 3.3 2.68 90 35.1% −0.72 [−1.02, −0.42]
Total (95% CI) 205 183 100.0% −0.26 [−0.76, 0.25]
Heterogeneity: Chi2= 11.99, df = 2 (P = 0.002); I2 = 83%
Test for overall eﬀect: Z = 0.99 (P = 0.32)
−2 0 1 2−1
Favours yoga Favours control
Chattha et al., 2008 [44] 1.47 1.3 54 1.95 1.3 54 50.6% −0.37 [−0.75, 0.01]
Elavsky and McAuley,
2007 [45]
1.72 1.6 61 1.29 1.27 39 49.4% 0.29 [−0.12, 0.69]
Total (95% CI) 115 93 100.0% −0.04 [−0.68, 0.60]
Heterogeneity: Chi2= 5.35, df = 1 (P = 0.02); I2 = 81%
Test for overall eﬀect: Z = 0.13 (P = 0.90)
−2 0 1 2−1
Favours yoga Favours control
Elavsky and McAuley,
2007 [45] 0.9 1 61 0.87 0.93 39 48.5% 0.03 [−0.37, 0.43]
Joshi et al., 2011 [46] 0.75 1.22 90 2.17 2.35 90 51.5% −0.76 [−1.06, −0.45]
Total (95% CI) 151 129 100.0% −0.37 [−1.14, 0.40]
Heterogeneity: Chi2= 9.37, df = 1 (P = 0.002); I2 = 89%
Test for overall eﬀect: Z = 0.95 (P = 0.34)
Psychological symptoms
Total menopausal symptoms
Somatic symptoms
Vasomotor symptoms
Urogenital symptoms
Study
Yoga Control
Mean SD Total Mean SD Total Weight IV, random, 95% CI IV, random, 95% CI
Std. mean diﬀerence Std. mean diﬀerence
Study
Yoga Control
Mean SD Total Mean SD Total Weight IV, random, 95% CI IV, random, 95% CI
Std. mean diﬀerence Std. mean diﬀerence
Study
Yoga Control
Mean SD Total Mean SD Total Weight IV, random, 95% CI IV, random, 95% CI
Std. mean diﬀerence Std. mean diﬀerence
Study
Yoga Control
Mean SD Total Mean SD Total Weight IV, random, 95% CI IV, random, 95% CI
Std. mean diﬀerence Std. mean diﬀerence
Study
Yoga Control
Mean SD Total Mean SD Total Weight IV, random, 95% CI IV, random, 95% CI
Std. mean diﬀerence Std. mean diﬀerence
Figure 2: Forest plots of overall short-term eﬀects of yoga on menopausal symptoms.
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Table 3: Subgroup analyses: eﬀect sizes of yoga versus controls.
Outcome No. of studies
No. of patients No. of patients Standardized mean diﬀerence P Heterogeneity
(yoga) (control) [95% confidence interval] (overall eﬀect) I2; Chi2; P
Yoga versus no treatmenta
Total symptoms 3 166 144 −0.53 [−1.19, 0.14] 0.12 85%; 13.05; <0.01
Psychological symptoms 3 166 144 −0.36 [−0.81, 0.09] 0.12 68%; 6.23; 0.04
Somatic symptoms 2 151 129 −0.38 [−1.08, 0.33] 0.29 87%, 7.86; <0.01
Vasomotor symptoms — — — — — —
Urogenital symptoms 2 151 129 −0.37 [−1.14, 0.40] 0.34 89%; 9.37; <0.01
Yoga versus exercisea
Total symptoms 2 76 77 0.10 [−0.37, 0.58] 0.67 38%; 1.61; 0.20
Psychological symptoms 3 130 131 0.10 [−0.43, 0.62] 0.72 75%; 7.93; 0.02
Somatic symptoms 2 115 117 0.06 [−0.20, 0.32] 0.66 0%; 0.17; 0.68
Vasomotor symptoms 2 115 117 −0.13 [−0.58, 0.33] 0.58 67%, 3.07; 0.08
Urogenital symptoms 2 151 129 −0.37 [−1.14, 0.40] 0.34 89%; 9.37; <0.01
a
Reference [42, 45] with one control arm each.
symptoms, psychological symptoms, somatic symptoms,
vasomotor symptoms, or urogenital symptoms (Table 3).
Since only 1 RCT with low risk of bias was included in
the meta-analyses, no formal sensitivity analysis of the eﬀects
on psychological symptoms was possible. However, the RCT
with low risk of bias [46] had higher eﬀect size and narrower
confidence intervals than the RCTs with high risk of bias [42,
44, 45] (Figure 2).
3.3.2. Risk of Bias across Studies. Since less than 10 studies
were included in each meta-analysis, funnel plots were not
analyzed.
3.4. Discussion. This systematic review found moderate
evidence for short-term improvements of psychological
symptoms in menopausal women after yoga interventions.
However, no evidence was found for improvements regard-
ing somatic, vasomotor, urogenital, or total menopausal
symptoms. Further, no group diﬀerence was found when
comparing yoga to exercise. The available safety data suggest
that yoga is not associated with serious adverse events. How-
ever, future RCTs should ensure more rigorous reporting of
adverse events and reasons for dropouts.
The conclusions of the present review are not in line
with a recent qualitative systematic review on mind-body
interventions, which concluded that there was moderate evi-
dence that yogamight relief commonmenopausal symptoms
including vasomotor and psychological symptoms [47]. On
the other hand, the finding of a small significant reduction of
psychological symptoms in the present review is also not in
line with another systematic review that concluded that yoga
is ineﬀective in relieving any menopausal symptoms includ-
ing psychological symptoms [30]. Diﬀerences in inclusion
criteria such as the inclusion of nonrandomized studies in
both aforementioned reviews as well as new evidence that is
now available [42, 43, 46] might at least partly explain the
diﬀerences in results. Therefore, the latter review included
much less RCTs and participants than the present one; for
example, 2 RCTs and 232 participants in the meta-analysis
on psychological symptoms [30], compared to 4 RCTs and
418 participants in the present review. The results of the
present review are, however, in line with those of a Cochrane
review that found no diﬀerences between yoga and exercise
in vasomotor symptom relief [48].
3.4.1. External and Internal Validity. Patients in the included
studies were recruited from inpatient clinics, outpatient
clinics, and yoga centers and by advertisements in North
America, South America, and Asia. Patients’ age ranged
from their mid-forties to their mid-fifties and members of
diﬀerent ethnic groups were included. Most studies included
peri- or postmenopausal women that were healthy besides
their menopausal symptoms; however, 1 study specifically
included only breast cancer survivors [43]. The results of
this review are therefore applicable to the vast majority
of women with menopausal symptoms in clinical practice.
External validity is however limited by the high frequency
of yoga sessions especially in the 2 Indian studies [44, 46].
Yoga programs that require daily meetings over several weeks
might be hard to establish in Western societies.
Three out of 5 studies had high risk of bias [42, 44, 45].
One of the 2 studies with low risk of bias [43, 46] could not
be included in the meta-analysis [43]. Adequate allocation
concealment was reported in only 2 studies, [43, 46],
and only 2 studies reported adequate blinding of outcome
assessors [43, 45]. Blinding patients or care providers in yoga
studies might not be possible at all [27]. No study that was
included in the meta-analysis applied adequate intention-
to-treat analysis. While no formal sensitivity analysis was
possible, the only RCT with low risk of bias that could be
included in the meta-analysis for psychological symptoms
[46] had higher eﬀect size and narrower confidence interval
than the RCTs with high risk of bias. While the eﬀects of
yoga on psychological symptoms therefore seem to be robust
against bias, definite judgments on internal validity of the
results cannot be drawn.
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3.4.2. Strengths andWeaknesses. This review is the first meta-
analysis available on menopausal symptoms that included
only randomized controlled trials. Moreover, in contrast
to the only other available meta-analysis on yoga for
menopausal symptoms [30], subgroup analyses for diﬀerent
types of control interventions were possible for almost all
prespecified outcome measures, and the levels of evidence
were determined according to established recommendations
[35].
The primary limitation of this paper is the small total
number of eligible RCTs. Moreover, since only 1 study
included a longer-term followup, no formal meta-analysis
on long-term eﬀects of yoga for menopausal symptoms
was possible. The overall high risk of bias further restricts
the interpretation of the results. Substantial statistical
heterogeneity was present in the significant meta-analysis
on psychological symptoms and subgroup analysis could
not provide reasons for heterogeneity. Further limitations
include the restriction of eligible publication languages, and
the use of compound scores for psychological symptoms in
most of the included studies. Therefore, the specific variables
that were improved by the yoga interventions, for example,
depression, anxiety, or sleep, could not be evaluated.
3.4.3. Implications for Further Research. Given the popular-
ity of yoga among patients with menopausal symptoms,
further studies are warranted. These studies should ensure
rigorous methodology and reporting, mainly adequate
randomization, allocation concealment, intention-to-treat
analysis, and blinding of at least outcome assessors [49].
Comparisons of yoga to adequately matched active control
interventions are equally needed as comparisons of diﬀerent
yoga styles. Dismantling studies that separately evaluate the
eﬀects of diﬀerent components of yoga such as physical
postures, breathing techniques, or meditation would further
improve knowledge of the underlying mechanisms of yoga in
menopausal symptom relief.
4. Conclusion
This systematic review found moderate evidence for short-
term eﬀectiveness of yoga for psychological symptom relief
in menopausal women. Since many menopausal women
request complementary therapies either instead of hormone
replacement therapy or in addition to it, yoga can be
preliminarily recommended as an adjunct intervention for
women who suﬀer from psychological complaints associated
with menopause. However, more rigorous research is needed
to underpin these results.
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